Iperion's asset base fell to NZ$0.3m, the smallest on record

Total equity fell in step, down 56.8% to NZ$0.2m, while total liabilities reduced to NZ$0.1m.

Revenue remained at zero in both HY26 and HY25, consistent with the company's recent history of no sales income. The reported loss narrowed: profit before tax moved from –NZ$0.4m to –NZ$0.2m, and net profit after tax mirrored that improvement because the effective tax rate stayed at 0.0%, equal to its historical mean.

Net operating cash outflow eased to –NZ$0.2m from –NZ$0.3m, and closing cash actually rose to NZ$0.2m from NZ$0.1m a year earlier — the only line on the balance sheet moving in the opposite direction to total assets.

With total assets at an unprecedented low of NZ$0.3m versus a historical mean of NZ$1.5m, and equity at NZ$0.2m, Iperion's funding capacity sits below anything in the supplied historical window. This matters because the company continues to spend roughly NZ$0.2m of operating cash per half, so the remaining equity base is small relative to demonstrated burn.

The second issue is that the improvement in reported loss happens against zero revenue. The percentage change in PBT and NPAT is flagged for basis discontinuity in the canonical metrics and is not analytically reliable as a growth rate, so the read is best framed in dollar terms: the loss is smaller because costs were lower, not because the business generated income. The antimicrobial licence — referenced in the release as containing minimum performance targets and a minimum royalty — has not produced reported revenue.

The third issue is the divergence between closing cash (up to NZ$0.2m) and total assets (down to NZ$0.3m). Cash now represents the bulk of the asset base, implying non-cash assets were either written down, derecognised, or simply not replenished, which raises a question about what productive capacity remains.

The supplied shape context shows HY25 carried 82% of FY25's NPAT and 60.9% of FY25's operating cash outflow, so on that pattern alone the second half could imply a smaller incremental loss than the first. That extrapolation is fragile because revenue is zero, cost behaviour is largely discretionary, and the implied FY25 second-half NPAT of –NZ$0.1m was itself small in absolute terms.

What the release does not support is any view on when, or whether, the antimicrobial licence will begin generating royalty income at the disclosed minimum levels. Without that, the result tells the reader how much burn occurred this half, not what the run-rate becomes once the licence activates.

There is no revenue to anchor the cost base against, no segment disclosure, no gross margin, and no working-capital cycle to read. The FCF-to-NPAT ratio of 115.9% is mathematically present but is a ratio of two negative numbers of similar magnitude and does not carry the usual meaning about cash quality.

Capex was zero in the period (the prior comparable had a small NZ$0.003m intangible purchase), which keeps free cash flow close to operating cash flow but also signals no investment activity in the underlying licence asset. Combined with the unprecedented-low total-asset base, the period reads as one of further balance-sheet shrinkage at a slower burn rate, rather than operational progress that can be extrapolated.

This briefing cannot assess the operational status of the antimicrobial licence, the recoverability of remaining intangible assets, or the company's ability to fund continued operations beyond the cash currently on hand.